Terms: = Colorectal cancer AND APC, DP2, 324, ENSG00000134982, P25054, FPC, GS, DP3, DP2_5 AND Clinical Outcome
28 results:
1. Chromosomal instability in adult-type diffuse gliomas.
Richardson TE; Walker JM; Abdullah KG; McBrayer SK; Viapiano MS; Mussa ZM; Tsankova NM; Snuderl M; Hatanpaa KJ
Acta Neuropathol Commun; 2022 Aug; 10(1):115. PubMed ID: 35978439
[TBL] [Abstract] [Full Text] [Related]
2. Genome-Derived Classification Signature for Ampullary Adenocarcinoma to Improve clinical cancer Care.
Chakraborty S; Ecker BL; Seier K; Aveson VG; Balachandran VP; Drebin JA; D'Angelica MI; Kingham TP; Sigel CS; Soares KC; Vakiani E; Wei AC; Chandwani R; Gonen M; Shen R; Jarnagin WR
Clin Cancer Res; 2021 Nov; 27(21):5891-5899. PubMed ID: 34433650
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive functional genomic analyses link apc somatic mutation and mRNA-miRNA networks to the clinical outcome of stage-III colorectal cancer patients.
Chiang SF; Huang HH; Tsai WS; Chin-Ming Tan B; Yang CY; Huang PJ; Yi-Feng Chang I; Lin J; Lu PS; Chin E; Liu YH; Yu JS; Chiang JM; Hung HY; You JF; Liu H
Biomed J; 2022 Apr; 45(2):347-360. PubMed ID: 35550340
[TBL] [Abstract] [Full Text] [Related]
4.
Disciglio V; Forte G; Fasano C; Sanese P; Lepore Signorile M; De Marco K; Grossi V; Cariola F; Simone C
Genes (Basel); 2021 Feb; 12(3):. PubMed ID: 33670833
[TBL] [Abstract] [Full Text] [Related]
5. Presentation and Follow-up of Familial Adenomatous Polyposis: Differences Between apc and MUTYH Mutations.
Bademci R; Bollo J; Ramón Y Cajal T; Martínez MC; Hernández MP; Targarona EM
Cir Esp (Engl Ed); 2020 Oct; 98(8):465-471. PubMed ID: 32505560
[TBL] [Abstract] [Full Text] [Related]
6. apc truncating mutations in Middle Eastern Population: Tankyrase inhibitor is an effective strategy to sensitize apc mutant CRC To 5-FU chemotherapy.
Siraj AK; Kumar Parvathareddy S; Pratheeshkumar P; Padmaja Divya S; Ahmed SO; Melosantos R; Begum R; Concepcion RMJA; Al-Sanea N; Ashari LH; Abduljabbar A; Al-Dayel F; Al-Kuraya KS
Biomed Pharmacother; 2020 Jan; 121():109572. PubMed ID: 31704613
[TBL] [Abstract] [Full Text] [Related]
7. The prognostic significance of p63 cytoplasmic expression in colorectal cancer. An immunohistochemical study.
Albasri AM; Elkablawy MA; Ansari IA; Alhujaily AS; Khalil AA
Saudi Med J; 2019 May; 40(5):432-439. PubMed ID: 31056618
[TBL] [Abstract] [Full Text] [Related]
8. MicroRNA-binding site polymorphisms in genes involved in colorectal cancer etiopathogenesis and their impact on disease prognosis.
Schneiderova M; Naccarati A; Pardini B; Rosa F; Gaetano CD; Jiraskova K; Opattova A; Levy M; Veskrna K; Veskrnova V; Buchler T; Landi S; Vodicka P; Vymetalkova V
Mutagenesis; 2017 Oct; 32(5):533-542. PubMed ID: 29048575
[TBL] [Abstract] [Full Text] [Related]
9. Tumor Heterogeneity Predicts Metastatic Potential in colorectal cancer.
Joung JG; Oh BY; Hong HK; Al-Khalidi H; Al-Alem F; Lee HO; Bae JS; Kim J; Cha HU; Alotaibi M; Cho YB; Hassanain M; Park WY; Lee WY
Clin Cancer Res; 2017 Dec; 23(23):7209-7216. PubMed ID: 28939741
[No Abstract] [Full Text] [Related]
10. Prognostic significance of USP33 in advanced colorectal cancer patients: new insights into β-arrestin-dependent ERK signaling.
Liu H; Zhang Q; Li K; Gong Z; Liu Z; Xu Y; Swaney MH; Xiao K; Chen Y
Oncotarget; 2016 Dec; 7(49):81223-81240. PubMed ID: 27835898
[TBL] [Abstract] [Full Text] [Related]
11. Genomic profiling of stage II and III colon cancers reveals apc mutations to be associated with survival in stage III colon cancer patients.
van den Broek E; Krijgsman O; Sie D; Tijssen M; Mongera S; van de Wiel MA; Belt EJ; den Uil SH; Bril H; Stockmann HB; Ylstra B; Carvalho B; Meijer GA; Fijneman RJ
Oncotarget; 2016 Nov; 7(45):73876-73887. PubMed ID: 27729614
[TBL] [Abstract] [Full Text] [Related]
12. Expression Pattern and Clinicopathological Relevance of the Indoleamine 2,3-Dioxygenase 1/Tryptophan 2,3-Dioxygenase Protein in colorectal cancer.
Chen IC; Lee KH; Hsu YH; Wang WR; Chen CM; Cheng YW
Dis Markers; 2016; 2016():8169724. PubMed ID: 27578919
[TBL] [Abstract] [Full Text] [Related]
13. XPG rs2296147 T>C polymorphism predicted clinical outcome in colorectal cancer.
Wang F; Zhang SD; Xu HM; Zhu JH; Hua RX; Xue WQ; Li XZ; Wang TM; He J; Jia WH
Oncotarget; 2016 Mar; 7(10):11724-32. PubMed ID: 26887052
[TBL] [Abstract] [Full Text] [Related]
14. RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth.
Depeille P; Henricks LM; van de Ven RA; Lemmens E; Wang CY; Matli M; Werb Z; Haigis KM; Donner D; Warren R; Roose JP
Nat Cell Biol; 2015 Jun; 17(6):804-15. PubMed ID: 26005835
[TBL] [Abstract] [Full Text] [Related]
15. miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan.
Schou JV; Rossi S; Jensen BV; Nielsen DL; Pfeiffer P; Høgdall E; Yilmaz M; Tejpar S; Delorenzi M; Kruhøffer M; Johansen JS
PLoS One; 2014; 9(6):e99886. PubMed ID: 24940606
[TBL] [Abstract] [Full Text] [Related]
16. MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer.
Valeri N; Braconi C; Gasparini P; Murgia C; Lampis A; Paulus-Hock V; Hart JR; Ueno L; Grivennikov SI; Lovat F; Paone A; Cascione L; Sumani KM; Veronese A; Fabbri M; Carasi S; Alder H; Lanza G; Gafa' R; Moyer MP; Ridgway RA; Cordero J; Nuovo GJ; Frankel WL; Rugge M; Fassan M; Groden J; Vogt PK; Karin M; Sansom OJ; Croce CM
Cancer Cell; 2014 Apr; 25(4):469-83. PubMed ID: 24735923
[TBL] [Abstract] [Full Text] [Related]
17. A functional germline variant in GLI1 implicates hedgehog signaling in clinical outcome of stage II and III colon carcinoma patients.
Szkandera J; Pichler M; Absenger G; Stotz M; Weissmueller M; Samonigg H; Asslaber M; Lax S; Leitner G; Winder T; Renner W; Gerger A
Clin Cancer Res; 2014 Mar; 20(6):1687-97. PubMed ID: 24470513
[TBL] [Abstract] [Full Text] [Related]
18. The prognostic significance of apc gene mutation and miR-21 expression in advanced-stage colorectal cancer.
Chen TH; Chang SW; Huang CC; Wang KL; Yeh KT; Liu CN; Lee H; Lin CC; Cheng YW
Colorectal Dis; 2013 Nov; 15(11):1367-74. PubMed ID: 23773491
[TBL] [Abstract] [Full Text] [Related]
19. Modeling clinical outcome using multiple correlated functional biomarkers: A Bayesian approach.
Long Q; Zhang X; Zhao Y; Johnson BA; Bostick RM
Stat Methods Med Res; 2016 Apr; 25(2):520-37. PubMed ID: 23070593
[TBL] [Abstract] [Full Text] [Related]
20. Methylation of the polycomb group target genes is a possible biomarker for favorable prognosis in colorectal cancer.
Dallol A; Al-Maghrabi J; Buhmeida A; Gari MA; Chaudhary AG; Schulten HJ; Abuzenadah AM; Al-Ahwal MS; Sibiany A; Al-Qahtani MH
Cancer Epidemiol Biomarkers Prev; 2012 Nov; 21(11):2069-75. PubMed ID: 23010642
[TBL] [Abstract] [Full Text] [Related]
[Next]
